CXCL12 and diabetes mellitus: RIP-SDF-1 transgenic mice expressing CXCL12 under the control of the insulin promoter, are to some extent protected against streptozotocin-induced diabetes, suggesting that CXCL12 agonists could provide beneficial effects in the treatment of diabetes [11].